194 related articles for article (PubMed ID: 18987047)
1. Angiogenesis inhibition in non-GIST soft tissue sarcomas.
Sleijfer S; van der Graaf WT; Blay JY
Oncologist; 2008 Nov; 13(11):1193-200. PubMed ID: 18987047
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenesis agents in the treatment of soft tissue sarcomas.
Ganjoo K; Jacobs C
Cancer; 2010 Mar; 116(5):1177-83. PubMed ID: 20052715
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis for the treatment of sarcoma.
Balasubramanian L; Evens AM
Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
[TBL] [Abstract][Full Text] [Related]
4. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
6. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
Mross K
Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
[No Abstract] [Full Text] [Related]
7. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
9. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
10. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
11. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.
Verheul HM; Hoekman K; Lupu F; Broxterman HJ; van der Valk P; Kakkar AK; Pinedo HM
Clin Cancer Res; 2000 Jan; 6(1):166-71. PubMed ID: 10656446
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy, a new player in the field of sarcoma treatment.
Versleijen-Jonkers YM; Vlenterie M; van de Luijtgaarden AC; van der Graaf WT
Crit Rev Oncol Hematol; 2014 Aug; 91(2):172-85. PubMed ID: 24613529
[TBL] [Abstract][Full Text] [Related]
13. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
14. [Antiangionic drugs in soft tissue sarcoma].
Salas S; Huynh T; Deville JL; Duffaud F
Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
[TBL] [Abstract][Full Text] [Related]
15. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
17. VEGF and myeloid leukemias.
Frankel AE; Gill PS
Leuk Res; 2004 Jul; 28(7):675-7. PubMed ID: 15158088
[TBL] [Abstract][Full Text] [Related]
18. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic strategies will be a revolution in lymphoma?
Paydas S
Leuk Res; 2010 Apr; 34(4):552. PubMed ID: 19819016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
